Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$9.15 - $11.09 $195,810 - $237,326
-21,400 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$10.24 - $20.87 $219,136 - $446,618
21,400 New
21,400 $219,000

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $17.8M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.